Bank of America Lifts LLY Price Target to $1,251 as Eli Lilly Nears 52-Week High
By TrendSpider Editor
Bank of America analyst Jason Gerberry reiterated a Buy rating on Eli Lilly and Company while raising his price target from $1,133 to $1,251, signaling renewed confidence in the pharmaceutical giant's outlook. LLY shares are trading at $1,115, up 2.84% on the session, putting the stock within striki
Bank of America Lifts LLY Price Target to $1,251 as Eli Lilly Nears 52-Week High
Bank of America analyst Jason Gerberry reiterated a Buy rating on Eli Lilly and Company while raising his price target from $1,133 to $1,251, signaling renewed confidence in the pharmaceutical giant's outlook. LLY shares are trading at $1,115, up 2.84% on the session, putting the stock within striking distance of its 52-week high of $1,133.95. With a 52-week low of $623.789, the stock has staged a remarkable recovery and is now trading near multi-month peaks.
Key Drivers of the LLY Stock Move
- Main Catalyst: Bank of America's Jason Gerberry confirmed a Buy rating on LLY and raised the price target to $1,251 from a prior target of $1,133, representing an increase of $118 in the firm's valuation estimate.
- Bull Case: The new $1,251 price target implies meaningful upside from the current price of $1,115. Combined with the stock's 2.84% gain today and its position near the 52-week high of $1,133.95, the BofA action reinforces a constructive technical and fundamental backdrop for LLY.
- Bear Case: LLY is trading near its 52-week high of $1,133.95, which could represent a zone of technical resistance. Investors buying at current levels are taking on elevated price risk should momentum stall or macro conditions shift, given the wide range between the 52-week low of $623.789 and today's price.
The forward setup for LLY looks constructive following BofA's target increase, which suggests the firm sees fundamental drivers that justify a higher valuation ceiling. The stock's proximity to its 52-week high of $1,133.95 means a sustained breakout above that level, supported by today's 2.84% move, could open the door toward the newly set $1,251 target. Eli Lilly has remained one of the most closely watched names in large-cap pharmaceuticals, driven by strong investor interest in its GLP-1 portfolio including tirzepatide, which anchors expectations for continued revenue growth. Any pipeline updates, commercial execution data, or guidance revisions from the company in the coming weeks could serve as additional catalysts to close the gap toward BofA's revised target.
LLY Analyst Ratings and Price Targets
Bank of America, through analyst Jason Gerberry, confirmed its Buy rating on Eli Lilly while raising its price target to $1,251 from a prior level of $1,133. This is the only analyst action in the current data set. The consensus average price target stands at $1,251, reflecting the updated BofA figure. There were no upgrades or downgrades in this action, only a reaffirmation of the existing positive stance alongside the higher target.
LLY Seasonality
Late May has historically been an active period for pharmaceutical sector re-ratings as analysts update models following first-quarter earnings seasons and medical conference season winds down. A price target increase at this point in the calendar often reflects updated commercial trajectory assumptions heading into the summer months.
LLY Relative Performance
LLY's 2.84% gain today places it well above the typical daily movement seen across large-cap pharmaceutical peers. Trading at $1,115 and approaching the 52-week high of $1,133.95, Eli Lilly is demonstrating relative strength versus the broader healthcare sector. The stock's recovery from a 52-week low of $623.789 underscores sustained outperformance on a trailing-year basis compared to many sector peers that have not seen comparable recoveries over the same window.